Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report

Patients with non‐small cell lung cancer (NSCLC) containing ROS1 fusions can have a marked response to the ROS1‐targeted tyrosine kinase inhibitors (TKIs), such as crizotinib. Common resistance mechanisms of ROS1‐fusion targeted therapy are acquired mutations in ROS1. Along with the use of next‐generation sequencing in the clinical management of patients with NSCLC during sequential targeted therapy, many mechanisms of acquired resistance have been discovered in patients with activated tyrosine kinase receptors. Besides acquired resistance mutations, bypass mechanisms of resistance to epidermal growth factor receptor (EGFR)‐TKI treatment are common in patients with EGFR mutations. Here we describe a patient with metastatic lung adenocarcinoma with CD74‐ROS1 fusion who initially responded to crizotinib and then developed resistance by the acquired mutation of D1228N in the MET kinase domain, which showed short‐term disease control for cabozantinib.Key Points

• The D1228N point mutation of MET is an acquired mutation for crizotinib resistance.
• The patient obtained short‐term clinical benefit from cabozantinib therapy after resistance to crizotinib.
• The clinical use of next‐generation sequencing could maximize the benefits of precision medicine in patients with cancer.

     

仿制药一致性评价的背景、实施及结局

我国是仿制药大国,开展仿制药质量和疗效一致性评价是国际惯例,也是我国经济、技术水平进步的必然结果。仿制药一致性评价适应国家新政,选择合适终点指标进行研究,目的是提高社会认可、实现仿制药与原研药的真正互换。仿制药一致性评价从简单的体外溶出度试验到系统的药学评价再到生物等效性评价,评价方法正在逐步完善,同时明确化学仿制药参比制剂遴选原则以减少仿制过程中的质量差异。仿制药一致性评价不仅能够提升我国制药行业的整体发展水平,促进医药产业升级和结构调整,同时可以节约医疗费用,保证患者用药安全。     

创伤性脊髓损伤后环状非编码RNA-微小RNA潜在调控网络信息挖掘

目的通过高通量测序获取创伤性脊髓损伤(traumatic spinal cord injury,TSCI)后环状非编码RNA(circular RNA,circRNA)与微小RNA(microRNA,miRNA)表达谱,预测潜在circRNA-miRNA调控网络。方法取48只雄性C57BL/6小鼠(体质量18~22 g)随机均分为两组(n=24),TSCI组采用Allen’s打击器械制备TSCI模型,假手术组(Sham组)仅切开椎板不损伤脊髓。术后3 d,两组取材行HE染色,观察脊髓组织结构;提取组织总RNA建库,高通量测序鉴定circRNA和miRNA差异表达谱,基因本体分析(gene ontology,GO)注释差异表达的circRNA宿主基因功能,筛选显著差异表达的miRNA,通过TargetScan和miRanda预测circRNAmiRNA靶向结合,筛选关键circRNA,构建潜在调控网络。结果HE染色示Sham组小鼠脊髓结构完整无破裂,TSCI组脊髓结构有明显损伤破裂。测序共鉴定出17440个circRNA、1228个miRNA。差异表达的circRNA宿主基因主要富集在细胞质,生物过程中差异基因主要富集在转录的正调控和蛋白磷酸化过程。差异表达最显著的miRNA为mmu-miR-21-5p,筛选出可与其靶向结合的circRNA6730,以circRNA6730为核心构建潜在circRNAmiRNA调控网络。结论通过表达谱分析和功能注释分析,显著差异表达的circRNA和miRNA有潜在的临床标志物价值,以circRNA6730为核心包含mmu-miR-21-5p的靶向互作网络可能在TSCI的发生发展过程中起重要调控作用,有助于阐明TSCI的病理生理进程机制,为临床诊疗提供新思路。     

SMILE术后眼前节变化对眼压测量值的影响

目的：探讨飞秒激光小切口角膜基质透镜取出术（SMILE）后眼压（IOP）检测的影响因素,分析眼前 节参数变化与IOP的关系。方法：前瞻性临床研究。收集2020年6—11月在青岛大学附属医院眼科 接受SMILE手术患者141例（258眼)的资料。根据剩余基质床厚度（RST）分为3组,分别为A组（280 μm     

基于Angiosome理念的腔内治疗干预糖尿病足的临床研究

目的:探讨Angiosome理念指导下的腔内治疗干预糖尿病足(DF)的效果。方法:选取滨州市沾化区人民医院、济南市中医医院和山东省立医院2015年1月—2018年1月收治的DF患者47例,随机分为Angiosome组和PTA组。Angiosome组患者基于Angiosome理念开展腔内治疗,PTA组患者常规开展PTA治疗。观察两组患者治疗前后踝肱压力指数(ABI)、疼痛视觉模拟评分(VAS)和随访期内截肢情况。结果:两组患者治疗后ABI和VAS评分较治疗前显著改善,Angiosome组患者ABI和VAS改善情况优于PTA组患者,随访期内截肢率低于PTA组。结论:基于Angiosome理念的腔内治疗可以显著改善DF患肢的缺血状态,有效降低截肢率。     

Distinct invasive patterns in situ between estrogen receptor-positive and triple-negative breast cancer through the intraductal tracking of carbon nanoparticles

Given that the transition from ductal carcinoma in situ (DCIS) to invasive breast cancer (BC) is crucial during the BC progression, the mechanism involved in the invasion transition behind triple-negative breast cancer (TNBC) and estrogen receptor-positive (ER-positive) subtype has remained elusive. This article detected distinct invasion patterns of BC cells between the ER-positive and TNBC using intraductal murine models with intraductal administration of carbon nanoparticles (CNPs). First, the feasibility of the utility of CNPs as a tracer was proved. The area ratio of CNPs and tumor cells invading the stroma at the late stage was found significantly higher than that in the early stage in MNU-induced ER-positive BC. However, opposite results were obtained in the triple-negative model. Consequently, we proposed that the ER-positive phenotype cells behave differently between different stages during tumor progression while there is no such difference in the invasion process of TNBC cells. The analysis regarding the duct integrity along with immunohistochemical characteristics further explained the distinct invasion features between the ER-positive and triple-negative subtypes. Last, the relationship between the duct thickness and the duct integrity suggested that ER-positive tumors gradually increased in size within the lumen before the invasion. Overall, this study suggested the different invasion characteristics of ER-positive BC and TNBC in vivo.